You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明系續受壓 藥明生物(02269.HK)及藥明康德(02359.HK)逆市續挫4%至5%
藍籌藥明康德(02359.HK)重申業務發展並不會對任何國家安全構成風險及澄清無贊助軍民融合項目。然而,該股繼上周五(26日)曾急挫至52.55元創近四年低喘定後,今早仍反覆受壓,早段回升至66.35元無以為繼,掉頭低見60.6元,現報61.25元,逆市續挫5.2%,暫為最傷藍籌,成交逾975萬股,涉6.18億元。 同系藍籌藥明生物(02269.HK)澄清,公司首席執行官及執行董事陳智勝從未在軍事醫學科學院或任何具有軍事背景機構工作。然而,該股繼上周五曾急挫至21.65元創約五年低喘定後,今早股價回升至25.7元無以為繼,掉頭倒跌4.5%報23.45元,成交6,644.8萬股,涉逾16.4億元。 同系半新股藥明合聯(02268.HK)現微跌0.2%,報25.15元,成交6,459.2萬元。藥明巨諾-B(02126.HK)現跌3.1%,報1.89元,成交88.9萬元。 不過,其他CXO股走個別,康龍化成(03759.HK)現反彈2.3%,報10.74元,成交1.1億元。泰格醫藥(03347.HK)微升0.6%,報26.9元,成交4,951.3萬元。昭衍新藥(06127.HK)則跌1.6%,報9.96元,成交329萬元。 恆指現報16,165,回升213點或1.3%,總成交額450億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account